A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Tirzepatide (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly; Eli Lilly and Company
- 11 Oct 2018 Results published in the Lancet.
- 04 Oct 2018 According to an Eli Lilly media release, the results were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes in Berlin and simultaneously published in The Lancet.
- 04 Oct 2018 Results presented in an Eli Lilly media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History